Ionis

Pharma

Lilly-InnoCare, Elevar, China's 5-year plan—Fierce Pharma Asia

Lilly and InnoCare inked a potential $3.35 billion deal. The FDA approved a novel cancer drug in a first for Korea. China set an ambitious five-year plan.

Angus Liu Sep 25, 2026 9:38am

Heart on futuristic podium with neon lighting

ESC: AZ digs deep on Wainua's surprise ph. 3 failure in ATTR-CM

Aug 29, 2026 1:35pm

head to head against clash football helmets fight combat

Arrowhead data set up Redemplo for hypertriglyceridemia nod

Jul 22, 2026 10:52am

Downward arrow superimposed in front of money

AstraZeneca, Ionis shares slide with ATTR-CM trial failure

Jul 9, 2026 11:36am

FDA approves transformational expansion of Ionis’ Tryngolza

Jun 25, 2026 8:13am

Space shuttle takes off on background of blue sky

As questions swirl, Alnylam eyes ATTR market leadership by 2030

Mar 26, 2026 2:08pm